Table 2

B cell phenotypes in IgG4-RD, pSS and healthy controls
Healthy controls IgG4-RD pSS IgG4-related disease versus HC pSS versus HC IgG4-RD versus pSS
P-value P-value P-value
CD19+ (%)1 4.41 ± 1.75 6.43 ± 2.73 8.97 ± 4.40 0.001 <0.001 0.009
CD19 + CD24 + CD38- (%)2 14.01 ± 10.39 22.71 ± 12.81 15.79 ± 10.58 0.002 0.541 0.009
CD19 + CD24intCD38int (%)2 53.70 ± 15.12 36.68 ± 14.27 49.75 ± 11.59 <0.001 0.150 <0.001
CD19 + CD24hiCD38hi (%)2 3.98 ± 2.70 2.17 ± 3.96 12.55 ± 5.15 <0.001 <0.001 <0.001
CD19 + CD24-CD38hi (%)2 2.16 ± 1.65 6.99 ± 6.24 2.39 ± 2.64 <0.001 0.868 <0.001
CD19 + CD40+ (%)2 87.08 ± 11.27 44.35 ± 21.79 69.48 ± 20.33 <0.001 <0.001 <0.001
CD19 + BAFF-R + (%)2 94.13 ± 3.50 76.63 ± 20.85 88.96 ± 8.90 0.001 0.005 0.066
CD19 + CD80+ (%)2 17.54 ± 7.41 43.27 ± 8.64 23.69 ± 14.24 <0.001 0.327 0.037
CD19 + CD86+ (%)2 19.56 ± 7.70 47.18 ± 14.23 27.45 ± 12.17 0.002 0.325 0.041

Values are shown as mean ± SD. 1Percentages of CD19+ cells in total lymphocytes. 2Percentages of B cell subsets in CD19+ cells. IgG4-RD, IgG4-related disease; pSS, primary Sjögren’s syndrome.

Lin et al.

Lin et al. Arthritis Research & Therapy 2014 16:R118   doi:10.1186/ar4571

Open Data